Management of Microcomplications of Diabetes Mellitus: Challenges, Current Trends, and Future Perspectives in Treatment
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Diabetes mellitus is a chronic metabolic disorder characterized by high blood sugar levels, which can lead to severe health issues if not managed effectively. Recent statistics indicate a significant global impact, with 463 million adults diagnosed worldwide and this projected to rise to 700 million by 2045. Type 1 diabetes is an autoimmune disorder where the immune system attacks pancreatic beta cells, reducing insulin production. Type 2 diabetes is primarily due to insulin resistance. Both types of diabetes are linked to severe microvascular and macrovascular complications if unmanaged. Microvascular complications, such as diabetic retinopathy, nephropathy, and neuropathy, result from damage to small blood vessels and can lead to organ and tissue dysfunction. Chronic hyperglycemia plays a central role in the onset of these complications, with prolonged high blood sugar levels causing extensive vascular damage. The emerging treatments and current research focus on various aspects, from insulin resistance to the intricate cellular damage induced by glucose toxicity. Understanding and intervening in these pathways are critical for developing effective treatments and managing diabetes long term. Furthermore, ongoing health initiatives, such as increasing awareness, encouraging early detection, and improving treatments, are in place to manage diabetes globally and mitigate its impact on health and society. These initiatives are a testament to the collective effort to combat this global health challenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“From a clinical perspective, achieving a reduction of at least 0.5% in HbA1c is widely recognized as a crucial threshold capable of substantially mitigating the risk of both microvascular and macrovascular complications.2”
From Nurse-Led Psychoeducational Interventions for Glycemic and Psychosocial Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis (2026) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
Pathophysiology of type 2 diabetes mellitus
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176275 · Cited by 3,360 · cited 3×
“Factors contributing to insulin resistance include obesity, sedentary lifestyles, poor diet, and genetic predisposition [1,5].”
BackgroundVrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602 · cited 1×
“Diabetic neuropathy is a condition characterized by the symptoms and signs of peripheral nerve dysfunction in patients with diabetes [83].”
BackgroundFeldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients
Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A., & Sakharkar, M. K. (2016) · Biomarker Insights · doi:10.4137/bmi.s38440 · Cited by 1,381
Hart, G. W., Slawson, C., Ramirez-Correa, G., & Lagerlof, O. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060608-102511 · Cited by 1,317 · cited 1×
“…differences in individual metabolism, and the presence of other co-morbid conditions are also crucial to the development and progression of complications, underscoring that this hypothesis is part of a larger picture that includes multiple biochemical, genetic, and environmental factors [29,30].”
BackgroundAhmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120 · cited 1×
“Preventive measures, effective treatment, and lifestyle interventions are crucial in managing this condition and curbing its impact on health and society [6,7].”
BackgroundDiabetic retinopathy: current understanding, mechanisms, and treatment strategies
Duh, E. J., Sun, J. K., & Stitt, A. W. (2017) · JCI Insight · doi:10.1172/jci.insight.93751 · Cited by 1,057 · cited 1×
“Furthermore, photoreceptor cells have been found to produce inflammatory products that contribute to retinal vascular permeability in diabetic conditions [56,57].”
BackgroundGut microbiota and cardiovascular disease.
Witkowski, M., Weeks, T. L., & Hazen, S. L. (2020) · Circulation Research · doi:10.1161/circresaha.120.316242 · Cited by 1,051
Research works printed but not linked: 138
- Wild, 2004, Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030, Diabetes Care, 27, 1047, 10.2337/diacare.27.5.1047 · DOI · Paper page
- Martinez-Ortega, A.J., Munoz-Gomez, C., Gros-Herguido, N., Remon-Ruiz, P.J., Acosta-Delgado, D., Losada-Vinau, F., Pumar-Lopez, A., Mangas-Cruz, M.A., Gonzalez-Navarro, I., and Lopez-Gallardo, G. (2022). Description of a Cohort of Type 1 Diabetes Patients: Analysis of Comorbidities, Prevalence of Complications and Risk of Hypoglycemia. J. Clin. Med., 11. · DOI
- Dabelea, 2009, The accelerating epidemic of childhood diabetes, Lancet, 373, 1999, 10.1016/S0140-6736(09)60874-6 · DOI · Paper page
- Li, 2007, Common pathological processes in Alzheimer disease and type 2 diabetes: A review, Brain Res. Rev., 56, 384, 10.1016/j.brainresrev.2007.09.001 · DOI · Paper page
- Nguyen, T.T., Ta, Q.T.H., Nguyen, T.K.O., Nguyen, T.T.D., and Giau, V.V. (2020). Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease. Int. J. Mol. Sci., 21. · DOI · Paper page
- Soyoye, 2021, Diabetes and peripheral artery disease: A review, World J. Diabetes, 12, 827, 10.4239/wjd.v12.i6.827 · DOI · Paper page
- Vithian, 2010, Microvascular complications: Pathophysiology and management, Clin. Med., 10, 505, 10.7861/clinmedicine.10-5-505 · DOI
- Zakir, 2023, Cardiovascular Complications of Diabetes: From Microvascular to Macrovascular Pathways, Cureus, 15, e45835
- Marcovecchio, 2011, Role of chronic and acute hyperglycemia in the development of diabetes complications, Diabetes Technol. Ther., 13, 389, 10.1089/dia.2010.0146 · DOI
- Brownlee, 2005, The pathobiology of diabetic complications: A unifying mechanism, Diabetes, 54, 1615, 10.2337/diabetes.54.6.1615 · DOI · Paper page
- Brownlee, 2001, Biochemistry and molecular cell biology of diabetic complications, Nature, 414, 813, 10.1038/414813a · DOI · Paper page
- Kowalczyk, P., Sulejczak, D., Kleczkowska, P., Bukowska-Osko, I., Kucia, M., Popiel, M., Wietrak, E., Kramkowski, K., Wrzosek, K., and Kaczynska, K. (2021). Mitochondrial Oxidative Stress-A Causative Factor and Therapeutic Target in Many Diseases. Int. J. Mol. Sci., 22. · DOI · Paper page
- Tang, W.H., Martin, K.A., and Hwa, J. (2012). Aldose reductase, oxidative stress, and diabetic mellitus. Front. Pharmacol., 3. · DOI · Paper page
- Singh, M., Kapoor, A., and Bhatnagar, A. (2021). Physiological and Pathological Roles of Aldose Reductase. Metabolites, 11. · DOI · Paper page
- Lorenzi, 2007, The polyol pathway as a mechanism for diabetic retinopathy: Attractive, elusive, and resilient, Exp. Diabetes Res., 2007, 61038, 10.1155/2007/61038 · DOI · Paper page
- Khalid, M., Petroianu, G., and Adem, A. (2022). Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. Biomolecules, 12. · DOI · Paper page
- Yamagishi, 2005, Advanced glycation end products (AGEs) and diabetic vascular complications, Curr. Diabetes Rev., 1, 93, 10.2174/1573399052952631 · DOI · Paper page
- Nguyen, D.V., Shaw, L.C., and Grant, M.B. (2012). Inflammation in the pathogenesis of microvascular complications in diabetes. Front. Endocrinol., 3. · DOI · Paper page
- Penn, 2008, Vascular endothelial growth factor in eye disease, Prog. Retin. Eye Res., 27, 331, 10.1016/j.preteyeres.2008.05.001 · DOI · Paper page
- Geraldes, 2010, Activation of protein kinase C isoforms and its impact on diabetic complications, Circ. Res., 106, 1319, 10.1161/CIRCRESAHA.110.217117 · DOI · Paper page
- Pan, D., Xu, L., and Guo, M. (2022). The role of protein kinase C in diabetic microvascular complications. Front. Endocrinol., 13. · DOI
- Zochodne, 2008, Diabetic polyneuropathy: An update, Curr. Opin. Neurol., 21, 527, 10.1097/WCO.0b013e32830b84cb · DOI
- Reddy, 2013, Epigenetic modifications in the pathogenesis of diabetic nephropathy, Semin. Nephrol., 33, 341, 10.1016/j.semnephrol.2013.05.006 · DOI
- Brasacchio, 2009, Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail, Diabetes, 58, 1229, 10.2337/db08-1666 · DOI · Paper page
- Feng, 2016, miR-200b Mediates Endothelial-to-Mesenchymal Transition in Diabetic Cardiomyopathy, Diabetes, 65, 768, 10.2337/db15-1033 · DOI
- Putta, 2012, Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy, J. Am. Soc. Nephrol., 23, 458, 10.1681/ASN.2011050485 · DOI · Paper page
- Yan, 2014, Aberrant expression of long noncoding RNAs in early diabetic retinopathy, Investig. Ophthalmol. Vis. Sci., 55, 941, 10.1167/iovs.13-13221 · DOI · Paper page
- Zampetaki, 2010, Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes, Circ. Res., 107, 810, 10.1161/CIRCRESAHA.110.226357 · DOI · Paper page
- Tang, 2017, Increased Trimethylamine N-Oxide Portends High Mortality Risk Independent of Glycemic Control in Patients with Type 2 Diabetes Mellitus, Clin. Chem., 63, 297, 10.1373/clinchem.2016.263640 · DOI · Paper page
- Zhao, 2013, The gut microbiota and obesity: From correlation to causality, Nat. Rev. Microbiol., 11, 639, 10.1038/nrmicro3089 · DOI · Paper page
- Shah, J., Cheong, Z.Y., Tan, B., Wong, D., Liu, X., and Chua, J. (2022). Dietary Intake and Diabetic Retinopathy: A Systematic Review of the Literature. Nutrients, 14. · DOI
- Wang, W., and Lo, A.C.Y. (2018). Diabetic Retinopathy: Pathophysiology and Treatments. Int. J. Mol. Sci., 19. · DOI · Paper page
- Rodriguez, 2019, Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies, Oxidative Med. Cell. Longev., 2019, 4940825, 10.1155/2019/4940825 · DOI · Paper page
- Kupis, 2022, Novel therapies for diabetic retinopathy, Cent. Eur. J. Immunol., 47, 102, 10.5114/ceji.2022.112993 · DOI
- Kastelan, S., Oreskovic, I., Biscan, F., Kastelan, H., and Gverovic Antunica, A. (2020). Inflammatory and angiogenic biomarkers in diabetic retinopathy. Biochem. Med., 30. · DOI · Paper page
- Thomas, 2019, IDF Diabetes Atlas: A review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018, Diabetes Res. Clin. Pract., 157, 107840, 10.1016/j.diabres.2019.107840 · DOI · Paper page
- Forrester, J.V., Kuffova, L., and Delibegovic, M. (2020). The Role of Inflammation in Diabetic Retinopathy. Front. Immunol., 11. · DOI · Paper page
- Tang, 2011, Inflammation in diabetic retinopathy, Prog. Retin. Eye Res., 30, 343, 10.1016/j.preteyeres.2011.05.002 · DOI · Paper page
- Santiago, A.R., Boia, R., Aires, I.D., Ambrosio, A.F., and Fernandes, R. (2018). Sweet Stress: Coping With Vascular Dysfunction in Diabetic Retinopathy. Front. Physiol., 9. · DOI
- Altmann, C., and Schmidt, M.H.H. (2018). The Role of Microglia in Diabetic Retinopathy: Inflammation, Microvasculature Defects and Neurodegeneration. Int. J. Mol. Sci., 19. · DOI · Paper page
- Whitehead, 2018, Diabetic retinopathy: A complex pathophysiology requiring novel therapeutic strategies, Expert. Opin. Biol. Ther., 18, 1257, 10.1080/14712598.2018.1545836 · DOI · Paper page
- Kastelan, 2013, Inflammation and pharmacological treatment in diabetic retinopathy, Mediat. Inflamm., 2013, 213130, 10.1155/2013/213130 · DOI
- Gouliopoulos, 2018, Association of serum inflammatory markers and diabetic retinopathy: A review of literature, Eur. Rev. Med. Pharmacol. Sci., 22, 7113
- Yang, J., and Liu, Z. (2022). Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy. Front. Endocrinol., 13. · DOI · Paper page
- Fu, 2019, Dyslipidemia in retinal metabolic disorders, EMBO Mol. Med., 11, e10473, 10.15252/emmm.201910473 · DOI
- Lu, 2018, Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review, J. Ophthalmol., 2018, 1694187
- Sweeney, M., and Foldes, G. (2018). It Takes Two: Endothelial-Perivascular Cell Cross-Talk in Vascular Development and Disease. Front. Cardiovasc. Med., 5. · DOI · Paper page
- Hernandez, 2019, Diabetic Retinopathy in the Context of Patients with Diabetes, Ophthalmic Res., 62, 211, 10.1159/000499541 · DOI · Paper page
- Stitt, 2016, The progress in understanding and treatment of diabetic retinopathy, Prog. Retin. Eye Res., 51, 156, 10.1016/j.preteyeres.2015.08.001 · DOI · Paper page
- Maniadakis, 2019, Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review, Pharmacoeconomics, 37, 995, 10.1007/s40273-019-00800-w · DOI
- Alam, S., Sarker, M.M.R., Sultana, T.N., Chowdhury, M.N.R., Rashid, M.A., Chaity, N.I., Zhao, C., Xiao, J., Hafez, E.E., and Khan, S.A. (2022). Antidiabetic Phytochemicals From Medicinal Plants: Prospective Candidates for New Drug Discovery and Development. Front. Endocrinol., 13. · DOI · Paper page
- Aryaeian, 2017, Polyphenols and their effects on diabetes management: A review, Med. J. Islam. Repub. Iran., 31, 134, 10.14196/mjiri.31.134 · DOI · Paper page
- Delmas, D., Cornebise, C., Courtaut, F., Xiao, J., and Aires, V. (2021). New Highlights of Resveratrol: A Review of Properties against Ocular Diseases. Int. J. Mol. Sci., 22. · DOI
- Wang, 2022, Role of Oxidative Stress in Retinal Disease and the Early Intervention Strategies: A Review, Oxid. Med. Cell. Longev., 2022, 7836828, 10.1155/2022/7836828 · DOI
- Kang, Q., and Yang, C. (2020). Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol., 37. · DOI · Paper page
- Keegan, 2020, Lutein and zeaxanthin attenuates VEGF-induced neovascularisation in human retinal microvascular endothelial cells through a Nox4-dependent pathway, Exp. Eye Res., 197, 108104, 10.1016/j.exer.2020.108104 · DOI
- Mthembu, 2023, Sulforaphane: A nutraceutical against diabetes-related complications, Pharmacol. Res., 196, 106918, 10.1016/j.phrs.2023.106918 · DOI
- Tanito, 2005, Sulforaphane induces thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in mice, Investig. Ophthalmol. Vis. Sci., 46, 979, 10.1167/iovs.04-1120 · DOI · Paper page
- Valle, 2021, Protective role of vitamin D against oxidative stress in diabetic retinopathy, Diabetes Metab. Res. Rev., 37, e3447, 10.1002/dmrr.3447 · DOI
- Fernandez-Robredo, P., Gonzalez-Zamora, J., Recalde, S., Bilbao-Malave, V., Bezunartea, J., Hernandez, M., and Garcia-Layana, A. (2020). Vitamin D Protects against Oxidative Stress and Inflammation in Human Retinal Cells. Antioxidants, 9. · DOI
- Putz, 2022, Vitamin D in the Prevention and Treatment of Diabetic Neuropathy, Clin. Ther., 44, 813, 10.1016/j.clinthera.2022.03.012 · DOI
- Totolici, 2022, The role of vitamin D in the onset and progression of diabetic retinopathy, Rom. J. Ophthalmol., 66, 214
- Jiang, 2017, Epac1 Blocks NLRP3 Inflammasome to Reduce IL-1beta in Retinal Endothelial Cells and Mouse Retinal Vasculature, Mediat. Inflamm., 2017, 2860956, 10.1155/2017/2860956 · DOI
- Gu, 2022, Targeting Pyroptosis: New Insights into the Treatment of Diabetic Microvascular Complications, Evid.-Based Complement. Alternat Med., 2022, 5277673, 10.1155/2022/5277673 · DOI
- Zhang, 2023, Long noncoding RNA KCNQ1OT1 induces pyroptosis in diabetic corneal endothelial keratopathy, Am. J. Physiol.-Cell Physiol., 318, C346, 10.1152/ajpcell.00053.2019 · DOI
- Chen, 2020, The potential role of lncRNAs in diabetes and diabetic microvascular complications, Endocr. J., 67, 659, 10.1507/endocrj.EJ19-0574 · DOI
- Zhu, 2016, Upregulation of lncRNA MEG3 promotes hepatic insulin resistance via increasing FoxO1 expression, Biochem. Biophys. Res. Commun., 469, 319, 10.1016/j.bbrc.2015.11.048 · DOI
- You, 2016, Downregulation of Long Noncoding RNA Meg3 Affects Insulin Synthesis and Secretion in Mouse Pancreatic Beta Cells, J. Cell. Physiol., 231, 852, 10.1002/jcp.25175 · DOI · Paper page
- Akerman, 2017, Human Pancreatic beta Cell lncRNAs Control Cell-Specific Regulatory Networks, Cell Metab., 25, 400, 10.1016/j.cmet.2016.11.016 · DOI · Paper page
- Callaghan, 2015, Distal Symmetric Polyneuropathy: A Review, JAMA, 314, 2172, 10.1001/jama.2015.13611 · DOI · Paper page
- Callaghan, 2014, Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy, JAMA Neurol., 71, 1143, 10.1001/jamaneurol.2014.1279 · DOI · Paper page
- Yang, H., Sloan, G., Ye, Y., Wang, S., Duan, B., Tesfaye, S., and Gao, L. (2019). New Perspective in Diabetic Neuropathy: From the Periphery to the Brain, a Call for Early Detection, and Precision Medicine. Front. Endocrinol., 10. · DOI · Paper page
- Ling, 2020, The impact of diabetic foot ulcers and unilateral offloading footwear on gait in people with diabetes, Clin. Biomech., 73, 157, 10.1016/j.clinbiomech.2020.01.014 · DOI
- Miyashita, A., Kobayashi, M., Yokota, T., and Zochodne, D.W. (2023). Diabetic Polyneuropathy: New Strategies to Target Sensory Neurons in Dorsal Root Ganglia. Int. J. Mol. Sci., 24. · DOI
- Ishibashi, 2019, Improvement in Neuropathy Outcomes with Normalizing HbA(1c) in Patients with Type 2 Diabetes, Diabetes Care, 42, 110, 10.2337/dc18-1560 · DOI
- Veluchamy, 2017, Risk factors for neuropathic pain in diabetes mellitus, Pain, 158, 560, 10.1097/j.pain.0000000000000785 · DOI · Paper page
- Raputova, 2017, Sensory phenotype and risk factors for painful diabetic neuropathy: A cross-sectional observational study, Pain, 158, 2340, 10.1097/j.pain.0000000000001034 · DOI · Paper page
- Kim, 2012, Emerging therapy for diabetic neuropathy: Cell therapy targeting vessels and nerves, Endocr. Metab. Immune Disord. Drug Targets, 12, 168, 10.2174/187153012800493486 · DOI
- Komai, 2024, Vascular Disease and Diabetes, Ann. Vasc. Dis., 17, 109, 10.3400/avd.ra.24-00010 · DOI
- Zochodne, 2015, Diabetes and the plasticity of sensory neurons, Neurosci. Lett., 596, 60, 10.1016/j.neulet.2014.11.017 · DOI
- Sugimoto, 2002, Expression and localization of insulin receptor in rat dorsal root ganglion and spinal cord, J. Peripher. Nerv. Syst., 7, 44, 10.1046/j.1529-8027.2002.02005.x · DOI
- Zochodne, 1999, Diabetic neuropathies: Features and mechanisms, Brain Pathol., 9, 369, 10.1111/j.1750-3639.1999.tb00233.x · DOI · Paper page
- Pop-Busui, R., Ang, L., Boulton, A.J.M., Feldman, E.L., Marcus, R.L., Mizokami-Stout, K., Singleton, J.R., and Ziegler, D. (2022). Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy, American Diabetes Association. · DOI · Paper page
- Callaghan, 2012, Enhanced glucose control for preventing and treating diabetic neuropathy, Cochrane Database Syst. Rev., 6, CD007543
- Page, 2012, Clinical inquiry: What medications are best for diabetic neuropathic pain?, J. Fam. Pract., 61, 691
- Akter, S., Choubey, M., Mohib, M.M., Arbee, S., Sagor, M.A.T., and Mohiuddin, M.S. (2023). Stem Cell Therapy in Diabetic Polyneuropathy: Recent Advancements and Future Directions. Brain Sci., 13. · DOI
- Voute, 2021, Topical Lidocaine for Chronic Pain Treatment, Drug Des. Devel Ther., 15, 4091, 10.2147/DDDT.S328228 · DOI
- Volmer-Thole, M., and Lobmann, R. (2016). Neuropathy and Diabetic Foot Syndrome. Int. J. Mol. Sci., 17. · DOI · Paper page
- Cernea, 2021, Management of diabetic neuropathy, Metabolism, 123, 154867, 10.1016/j.metabol.2021.154867 · DOI
- Singh, 2014, Regeneration of diabetic axons is enhanced by selective knockdown of the PTEN gene, Brain, 137, 1051, 10.1093/brain/awu031 · DOI
- Cheng, 2017, A model of chronic diabetic polyneuropathy: Benefits from intranasal insulin are modified by sex and RAGE deletion, Am. J. Physiol. Endocrinol. Metab., 312, E407, 10.1152/ajpendo.00444.2016 · DOI
- Kobayashi, 2017, Diabetic polyneuropathy, sensory neurons, nuclear structure and spliceosome alterations: A role for CWC22, Dis. Model. Mech., 10, 215, 10.1242/dmm.028225 · DOI
- Chandrasekhar, 2021, Dual Specificity Phosphatases Support Axon Plasticity and Viability, Mol. Neurobiol., 58, 391, 10.1007/s12035-020-02119-6 · DOI
- Kaburagi, 2022, Systemic DNA/RNA heteroduplex oligonucleotide administration for regulating the gene expression of dorsal root ganglion and sciatic nerve, Mol. Ther. Nucleic Acids, 28, 910, 10.1016/j.omtn.2022.05.006 · DOI
- Kapranov, 2007, RNA maps reveal new RNA classes and a possible function for pervasive transcription, Science, 316, 1484, 10.1126/science.1138341 · DOI · Paper page
- Yao, 2022, Long non-coding RNA MALAT1 regulates retinal neurodegeneration through CREB signaling, EMBO Mol. Med., 14, e16660, 10.15252/emmm.202216660 · doi:10.15252/emmm.202216660
- Wu, 2020, Long non-coding RNA MALAT1 promotes the proliferation and migration of Schwann cells by elevating BDNF through sponging miR-129-5p, Exp. Cell Res., 390, 111937, 10.1016/j.yexcr.2020.111937 · DOI
- Radhakrishnan, 2021, Long Noncoding RNA MALAT1 and Regulation of the Antioxidant Defense System in Diabetic Retinopathy, Diabetes, 70, 227, 10.2337/db20-0375 · DOI
- Arunkumar, 2024, LncRNAs: The good, the bad, and the unknown, Biochem. Cell Biol., 102, 9, 10.1139/bcb-2023-0155 · DOI
- Hussein, 2023, Long non-coding RNAs: The hidden players in diabetes mellitus-related complications, Diabetes Metab. Syndr., 17, 102872, 10.1016/j.dsx.2023.102872 · DOI
- Ebrahimi, 2021, Therapeutic effects of stem cells in different body systems, a novel method that is yet to gain trust: A comprehensive review, Bosn. J. Basic. Med. Sci., 21, 672
- Kubiak, 2020, Stem-cell-based therapies to enhance peripheral nerve regeneration, Muscle Nerve, 61, 449, 10.1002/mus.26760 · DOI · Paper page
- Streckmann, 2022, Exercise and Neuropathy: Systematic Review with Meta-Analysis, Sports Med., 52, 1043, 10.1007/s40279-021-01596-6 · DOI
- Dagar, 2021, Diabetic nephropathy: A twisted thread to unravel, Life Sci., 278, 119635, 10.1016/j.lfs.2021.119635 · DOI
- Umanath, 2018, Update on Diabetic Nephropathy: Core Curriculum 2018, Am. J. Kidney Dis., 71, 884, 10.1053/j.ajkd.2017.10.026 · DOI · Paper page
- Paschou, 2018, Diabetic nephropathy in type 1 diabetes, Minerva Med., 109, 218
- Koch, 2020, Autophagy in diabetic nephropathy: A review, Int. Urol. Nephrol., 52, 1705, 10.1007/s11255-020-02545-4 · DOI
- Ying, 2022, Diabetes and other vascular risk factors in association with the risk of lower extremity amputation in chronic limb-threatening ischemia: A prospective cohort study, Cardiovasc. Diabetol., 21, 7, 10.1186/s12933-021-01441-0 · DOI
- Giri, 2018, Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity, Biomed. Pharmacother., 107, 306, 10.1016/j.biopha.2018.07.157 · DOI · Paper page
- Calle, P., and Hotter, G. (2020). Macrophage Phenotype and Fibrosis in Diabetic Nephropathy. Int. J. Mol. Sci., 21. · DOI · Paper page
- Mussap, 2005, Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes, J. Am. Soc. Nephrol., 16, S78, 10.1681/ASN.2004110961 · DOI · Paper page
- Wada, 2013, Inflammation and the pathogenesis of diabetic nephropathy, Clin. Sci., 124, 139, 10.1042/CS20120198 · DOI · Paper page
- Gupta, 2023, Diabetic Kidney Disease: An Update, Med. Clin. N. Am., 107, 689, 10.1016/j.mcna.2023.03.004 · DOI · Paper page
- Landstra, C.P., and de Koning, E.J.P. (2021). COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course. Front. Endocrinol., 12. · DOI · Paper page
- Salom, 2017, Natural antioxidants in the treatment and prevention of diabetic nephropathy; a potential approach that warrants clinical trials, Redox Rep., 22, 99, 10.1080/13510002.2017.1297885 · DOI
- Jia, 2019, Genistein attenuates renal fibrosis in streptozotocin-induced diabetic rats, Mol. Med. Rep., 19, 423
- Lachin, 2021, Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC), Diabetes Care, 44, 2216, 10.2337/dc20-3097 · DOI · Paper page
- Ahmad, 2015, Management of diabetic nephropathy: Recent progress and future perspective, Diabetes Metab. Syndr., 9, 343, 10.1016/j.dsx.2015.02.008 · DOI
- Cha, 2021, Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes, J. Clin. Endocrinol. Metab., 106, 1225, 10.1210/clinem/dgaa894 · DOI
- Tanase, D.M., Gosav, E.M., Anton, M.I., Floria, M., Seritean Isac, P.N., Hurjui, L.L., Tarniceriu, C.C., Costea, C.F., Ciocoiu, M., and Rezus, C. (2022). Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives. Biomolecules, 12. · DOI · Paper page
- Charlton, A., Garzarella, J., Jandeleit-Dahm, K.A.M., and Jha, J.C. (2020). Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes. Biology, 10. · DOI · Paper page
- Eltablawy, 2018, Vitamin D protection from rat diabetic nephropathy is partly mediated through Klotho expression and renin-angiotensin inhibition, Arch. Physiol. Biochem., 124, 461, 10.1080/13813455.2018.1423624 · DOI
- Ma, 2010, Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: Current status, Br. J. Pharmacol., 160, 1273, 10.1111/j.1476-5381.2010.00750.x · DOI · Paper page
- Mazzieri, A., Porcellati, F., Timio, F., and Reboldi, G. (2024). Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection. Int. J. Mol. Sci., 25. · DOI
- Zhang, 2018, The Long Noncoding RNA 150Rik Promotes Mesangial Cell Proliferation via miR-451/IGF1R/p38 MAPK Signaling in Diabetic Nephropathy, Cell Physiol. Biochem., 51, 1410, 10.1159/000495590 · doi:10.1159/000495590
- Huang, 2019, Long noncoding RNA NEAT1 accelerates the proliferation and fibrosis in diabetic nephropathy through activating Akt/mTOR signaling pathway, J. Cell Physiol., 234, 11200, 10.1002/jcp.27770 · DOI
- Mao, 2019, Astragaloside IV inhibits excessive mesangial cell proliferation and renal fibrosis caused by diabetic nephropathy via modulation of the TGF-beta1/Smad/miR-192 signaling pathway, Exp. Ther. Med., 18, 3053
- Hanson, 2007, Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study, Diabetes, 56, 975, 10.2337/db06-1072 · DOI
- Lin, B., Ma, Y.Y., and Wang, J.W. (2022). Nano-Technological Approaches for Targeting Kidney Diseases With Focus on Diabetic Nephropathy: Recent Progress, and Future Perspectives. Front. Bioeng. Biotechnol., 10. · DOI
- Ramos, 2020, Design and optimization strategies for the development of new drugs that treat chronic kidney disease, Expert. Opin. Drug Discov., 15, 101, 10.1080/17460441.2020.1690450 · DOI
- Faustino, C., and Pinheiro, L. (2020). Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy. Pharmaceutics, 12. · DOI · Paper page
- Rubin, 2020, Improving Molecular Therapy in the Kidney, Mol. Diagn. Ther., 24, 375, 10.1007/s40291-020-00467-6 · DOI
- Boonstra, 2018, Local delivery of liposomal prednisolone leads to an anti-inflammatory profile in renal ischaemia-reperfusion injury in the rat, Nephrol. Dial. Transplant., 33, 44, 10.1093/ndt/gfx204 · DOI
- Tandon, 2012, Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: Implications of the results of recent clinical trials in type 2 diabetes, Am. J. Cardiovasc. Drugs, 12, 7, 10.2165/11594650-000000000-00000 · DOI
- Milligan, 2016, Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation, J. Diabetes Complicat., 30, 1177, 10.1016/j.jdiacomp.2016.03.010 · DOI
- Tilinca, M.C., Tiuca, R.A., Tilea, I., and Varga, A. (2021). The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients. J. Pers. Med., 11. · DOI
- Hussain, 2019, The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus, Drugs, 79, 231, 10.1007/s40265-019-1061-4 · DOI
- Wronka, M., Krzemińska, J., Młynarska, E., Rysz, J., and Franczyk, B. (2023). New Insights into the Use of Liraglutide-Impact on Cardiovascular Risk and Microvascular Outcomes. Biomedicines, 11. · DOI
Cited by
Susanti, E., Kosasih, C., Priambodo, A., Juniarti, N., Aziz, M., & Afriana, R. (2026) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s605488
Metadata
- Authors
- Yapislar, H., & Gurler, E. B.
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2024-08-28
- Volume
- 12
- Issue
- 9
- Pages
- 1958
- ISSN
- 2227-9059
- Cited by
- 64
- References
- 24
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of Microcomplications of Diabetes Mellitus: Challenges, Current Trends, and Future Perspectives in Treatment. https://app.cochat.ai/papers/10.3390/biomedicines12091958
- The paper
- Yapislar, H., & Gurler, E. B. (2024). Management of Microcomplications of Diabetes Mellitus: Challenges, Current Trends, and Future Perspectives in Treatment. Biomedicines. https://doi.org/10.3390/biomedicines12091958
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.